ArticleThe Journal of clinical endocrinology and metabolism2022
Serum Estradiol and 20 Site-Specific Cancers in Women: Mendelian Randomization Study.
Article in The Journal of clinical endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Glycolytic Reprogramming in Endometriosis: Biological Basis and Emerging Targets for Disease-Modifying Therapy.Journal of clinical medicine · 2026Review
- Sex differences in non-reproductive cancers: mechanistic roles of sex-hormone signaling.Cell communication and signaling : CCS · 2026Review
- Adiposity and cancer: epidemiology, mechanisms and future perspectives.Nature metabolism · 2026Review
- The regulation of fatty acid mobilization is extravagant rather than frugal: a perspective indicating a limitation of the thrifty genotype hypothesis.The American journal of clinical nutrition · 2025Review
- Genetically proxied risk and protective factors for pancreatic cancer: a systematic review and meta-analysis of Mendelian randomization studies.Journal of gastrointestinal oncology · 2025Article
- The application of mendelian randomization in cancer research: a bibliometric analysis.Discover oncology · 2025Article
- Article
- Sex hormones and risk of lung and colorectal cancers in women: a Mendelian randomization study.Scientific reports · 2024Article
- A cause-effect relationship between uterine diseases and breast cancer: A bidirectional Mendelian randomization study.Heliyon · 2024Article
- A Narrative Review of the Role of Estrogen (Receptors) in Melanoma.International journal of molecular sciences · 2024Review
- Tumour-derived exosome SNHG17 induced by oestrogen contributes to ovarian cancer progression via the CCL13-CCR2-M2 macrophage axis.Journal of cellular and molecular medicine · 2024Article
- Sex hormones and risk of lung and colorectal cancers in women: a Mendelian randomization study.Research square · 2024Article
- Total Effective Xenoestrogen Burden in Serum Samples and Risk of Endometrial Cancer in the Spanish Screenwide Case-Control Study.Environmental health perspectives · 2024Article
- Causal effect analysis of estrogen receptor associated breast cancer and clear cell ovarian cancer.American journal of translational research · 2024Article
- Incorporating biological and clinical insights into variant choice for Mendelian randomisation: examples and principles.eGastroenterology · 2024Article
- Cheminformatics analysis of chemicals that increase estrogen and progesterone synthesis for a breast cancer hazard assessment.Scientific reports · 2022Article
- Mendelian randomization analysis of factors related to ovulation and reproductive function and endometrial cancer risk.BMC medicine · 2022Article
- Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women.Scientific reports · 2022Article
- Investigating the Effect of Estradiol Levels on the Risk of Breast, Endometrial, and Ovarian Cancer.Journal of the Endocrine Society · 2022Article
- Review of Mendelian Randomization Studies on Endometrial Cancer.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
contextThe causal role of endogenous estradiol in cancers other than breast and endometrial cancer remains unclear.
objectiveThis Mendelian randomization study assessed the causal associations of endogenous 17β-estradiol (E2), the most potent estrogen, with cancer risk in women.
methodsAs primary genetic instrument, we used a genetic variant in the CYP19A1 gene that is strongly associated with serum E2 levels. Summary statistics genetic data for the association of the E2 variant with breast, endometrial, and ovarian cancer were obtained from large-scale consortia. We additionally estimated the associations of the E2 variant with any and 20 site-specific cancers in 198 825 women of European descent in UK Biobank. Odds ratios (OR) of cancer per 0.01 unit increase in log-transformed serum E2 levels in pmol/L were estimated using the Wald ratio.
resultsGenetic predisposition to higher serum E2 levels was associated with increased risk of estrogen receptor (ER)-positive breast cancer (OR 1.02; 95% CI, 1.01-1.03; P = 2.5 × 10-3), endometrial cancer overall (OR 1.09; 95% CI, 1.06-1.11; P = 7.3 × 10-13), and endometrial cancer of the endometrioid histology subtype (OR 1.10; 95% CI, 1.07-1.13; P = 2.1 × 10-11). There were suggestive associations with breast cancer overall (OR 1.01; 95% CI, 1.00-1.02; P = 0.02), ovarian cancer of the endometrioid subtype (OR 1.05; 95% CI, 1.01-1.10; P = 0.02), and stomach cancer (OR 1.12; 95% CI, 1.00-1.26; P = 0.05), but no significant association with other cancers.
conclusionThis study supports a role of E2 in the development of ER-positive breast cancer and endometrioid endometrial cancer but found no strong association with other cancers in women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.